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Abstract 31 
The aim of this work was to prepare and evaluate the capability of zein 32 
nanoparticles for oral drug delivery. More particularly, in this work, the ability of 33 
these nanoparticles to improve the oral bioavailability of folic acid is reported. 34 
The nanoparticles were prepared by a desolvation process, followed by 35 
purification via ultrafiltration and drying in a spray-drier apparatus.  The resulting 36 
nanoparticles displayed a mean size close to 200 nm with negative zeta 37 
potential and a payload of 54 μg folic acid per mg nanoparticle. From the in vitro 38 
release studies, it was observed that folic acid was only released from 39 
nanoparticles in simulated intestinal conditions. In vivo biodistribution studies, 40 
with radiolabelled or fluorescently marked nanoparticles, revealed that 41 
nanoparticles remained within the gut and were capable of interacting with the 42 
protective mucus layer of the jejunum.  For the pharmacokinetic study, folic acid 43 
was orally administered to rats as a single dose of 1 mg/kg.  44 
The relatively oral bioavailability of folic acid, when encapsulated in zein 45 
nanoparticles, was around 70%: two-times higher than the value obtained with 46 
an aqueous solution of the vitamin. This fact might be explained by the 47 
mucoadhesive properties of these nanoparticles. 48 
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Introduction 55 
Zein, the major storage protein of maize, is located in the “zein-bodies”, of 56 
approximately 1 μm, that are distributed uniformly throughout the cytoplasm of 57 
the corn endosperm cells between starch granules of 5–35 μm [1]. From a 58 
physicochemical point of view, the key characteristic of zein is its insolubility in 59 
water except at extreme pH conditions (e.g., pH 11 or above) or in presence of 60 
high concentrations of urea, alcohol or anionic detergents [2]. This characteristic 61 
is directly related with its composition in amino acids. Thus, zein is particularly 62 
rich in glutamic acid (21–26%) and non-polar amino acids such as leucine 63 
(20%), proline (10%) and alanine (10%), but it is deficient in basic and acidic 64 
amino acids [3].  65 
Actually, zein is not a single protein but a mixture of four main fractions (α-, β-, 66 
γ-, and δ-zein) that differentiated in their solubility and sequence [1, 4]. Alpha-67 
zein is the most abundant (around 80% of total zein) and includes two prolamin 68 
groups with apparent molecular weights of 24 and 27 kDa. Beta-zein consists of 69 
a methionine-rich polypeptide of 17 kDa and constitutes up to 10% of the total 70 
zein; whereas γ-zein is also composed of two peptides of 27 and 18 kDa. 71 
Finally, δ-zein is a minor fraction and has a molecular weight of about 10 kDa 72 
[1, 4, 5]. 73 
Because of its hydrophobic character and deficiency in essential amino acids 74 
(e.g. lysine and tryptophan), the use of this corn protein in human food products 75 
is limited. However, zein has been proposed as material for the manufacture of 76 
a wide variety of products, including textile fibers for clothes [6], biodegradable 77 
films and plastics used for packaging [7], coatings for food and pharmaceutical 78 
dosage forms [8, 9] and scaffolds for tissue engineering [10]. 79 
In the last years, microparticles and nanoparticles from zein have also been 80 
studied as carriers of non-polar compounds including vitamin D3 [11], curcumin 81 
[12] or thymol [13]. Such devices were capable of protecting the loaded 82 
compounds from stomach harsh conditions and providing a mechanism for their 83 
controlled release [14, 15]. 84 
Folic acid (pteroyl-L-glutamic acid, vitamin B9) is a water soluble vitamin that is 85 
essential during periods of rapid cell division and growth. It is implicated in cell 86 
replication and has an important role in the one-carbon metabolic pathway, 87 
essential for cardiovascular and neurological functions [16]. During periods of 88 
inadequate folate intake or malabsorption, biochemical changes due to this lack 89 
of folic acid/folate may result in deleterious consequences, including increased 90 
risk for certain types of chronic diseases [17] and developmental disorders (e.g., 91 
neural tube defects) [18]. In this way, previous studies have shown that folate 92 
deficiency is associated with higher incidence of mental symptoms in general 93 
population and poor cognitive performance that may increase the risk of 94 
dementia in old age [18, 19]. Particularly in major depression, low folic acid 95 
levels are frequently described in clinical studies [20]. Corroborating these 96 
findings, a variety of controlled and open-label studies have shown that the 97 
efficacy of antidepressants is influenced by folate status and may be enhanced 98 
by folic acid supplementation [21]. On the other hand, low folate intake or low 99 
plasma folate concentration has also been associated with increased 100 
cardiovascular and cerebrovascular risks [22]. All of these effects would be 101 
related with high plasma levels of homocysteine, a cytotoxic sulfur-containing 102 
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amino acid that can induce DNA strand breakage, oxidative stress and 103 
apoptosis [22].  104 
Interestingly, folic acid supplementation might reduce the 105 
hyperhomocysteinaemia [23, 24]. However, the supply of folate coenzymes in 106 
vivo depends primarily on the quantity and bioavailability of ingested folic 107 
acid/folate and the rate of loss by urinary and fecal routes and through 108 
catabolism. Additionally, folate is highly susceptible to oxidative destruction. In 109 
fact, 50–95% of folate content in food is estimated to be lost during storage, 110 
preparation, or manufacturing processes [25].  111 
The aim of this work was to design and evaluate zein nanoparticles as carriers 112 
capable of improving the bioavailability of folic acid when orally administered. 113 
For this purpose, these zein nanoparticles were prepared by an original 114 
procedure and their capability to improve the oral bioavailability of folic acid was 115 
evaluated and compared with a conventional aqueous solution of the vitamin in 116 
rats. 117 
 118 
 119 
Materials and methods 120 
Materials 121 
Zein, folic acid, lysine, arginine, pepsin, pancreatin, mannitol and sodium 122 
chloride were purchased from Sigma-Aldrich (Steinheim, Germany). Ethanol, 123 
acetonitrile and o-phosphoric acid (HPLC grade) were obtained from Merck 124 
(Darmstadt, Germany). Perylene-Red (BASF Lumogen® F Red 305; Lumogen 125 
red) was from Kremer Pigments Inc. (Aichstetten, Germany) and Tissue-Tek® 126 
OCT compound from Sakura Finetek Europe (Alphen, The Netherlands). 4',6-127 
diamidino-2-phenylindole (DAPI) was obtained from  Biotium Inc. (Hayward, 128 
CA). Iodine 125 was from Perkin Elmer (USA). AccuDiag™ Folate-Folic acid 129 
ELISA Kit was purchased from Diagnostic Automation/Cortez Diagnostics Inc. 130 
(USA). Deionized water (18.2 MΩ resistivity) was prepared by a water 131 
purification system (Wasserlab, Spain). All reagents and chemicals used were 132 
of analytical grade. 133 
 134 
Preparation of zein nanoparticles 135 
Zein nanoparticles were prepared by a desolvation procedure followed by a 136 
purification step by ultrafiltration and subsequent drying in a spray-drier 137 
apparatus. 138 
 139 
Empty zein nanoparticles (NP-Z) 140 
Briefly, 600 mg zein and 100 mg lysine were firstly dissolved in 70 mL of a 141 
mixture of ethanol and water (1:1 by vol.) under magnetic stirring at room 142 
temperature. Then, nanoparticles were obtained by the continuous addition of 143 
70 mL purified water. The suspension was purified and concentrated by 144 
ultrafiltration using a membrane cartridge with a 50 kDa pore size polysulfone 145 
(Medica SPA, Italy). Finally, 20 mL of an aqueous solution of mannitol (100 146 
mg/mL) was added to the suspension of zein nanoparticles and the mixture was 147 
dried in a Büchi Mini Spray Drier B-290 apparatus (Büchi Labortechnik AG, 148 
Switzerland) under the following experimental conditions: (i) inlet temperature: 149 
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90°C, (ii) outlet temperature: 45-50°C, (iii) air pressure: 5 bar, (iv)  pumping rate: 150 
5 mL/min, (v) aspirator of 100% and (vi) air flow: 900 L/h. 151 
 152 
Folic acid-loaded zein nanoparticles (FA-NP-Z) 153 
The preparation of zein nanoparticles loaded with folic acid (FA-NP-Z) was 154 
similar to that of the empty particles, with some minor adjustments. For this 155 
purpose, 600 mg zein and 100 mg lysine were dissolved in 70 mL of a mixture 156 
of ethanol and water (1:1 by vol.). In parallel, 200 mg folic acid was dissolved in 157 
50 mL of an aqueous solution of lysine (4 mg/mL). Then, 15 mL of the aqueous 158 
folic acid solution were added to the zein solution and the resulting mixture was 159 
incubated at room temperature for 10 min under magnetic stirring. Finally, zein 160 
nanoparticles were obtained by the addition of 70 mL purified water. The 161 
suspension was purified and dried as described above. 162 
 163 
Characterization of nanoparticles 164 
Size, zeta potential and morphology 165 
The mean hydrodynamic diameter and the zeta potential of the nanoparticles 166 
were determined by photon correlation spectroscopy (PCS) and electrophoretic 167 
laser Doppler anemometry, respectively, using a Zetaplus apparatus 168 
(Brookhaven Instrument Corporation, USA). The diameter of the nanoparticles 169 
was determined after dispersion in distilled water (1:10) and was measured at 170 
25°C with a scattering angle of 90°. The zeta potential was measured after 171 
dispersion of the dried nanoparticles in 1 mM pH 6 KCl solution. 172 
The morphology and shape of nanoparticles was examined using a field 173 
emission scanning electron microscope FE-SEM (ULTRA Plus, Zeiss, The 174 
Netherlands). Prior to analysis, particles were washed to remove mannitol. For 175 
this purpose, spray-dried nanoparticles were resuspended in distilled water and 176 
centrifuged at 17,000 x g for 10 min. Then, the supernatants were discarded 177 
and the obtained pellets were mounted on copper grids. Finally, the pellet was 178 
shaded with an amalgam of gold/palladium during fifteen seconds using a 179 
sputter coater (K550X Emitech, Ashford, UK). 180 
 181 
Yield of the preparative process 182 
In order to quantify the amount of protein transformed into nanoparticles, 10 mg 183 
of the nanoparticle formulation were dispersed in water and centrifuged at 184 
17,000 x g for 20 min. Supernatants were discarded and the pellets were 185 
digested with ethanol 75%. Then, the amount of protein was quantified by UV 186 
spectrophotometry at 278 nm in an Agilent 8453 system (Agilent Technologies, 187 
USA). For analysis, calibration curves were constructed between 90 and 1200 188 
µg/mL (R2> 0.999; quantification limit = 143 µg/mL). 189 
The amount of protein forming nanoparticles in the formulation was estimated 190 
as the ratio between the amount of the protein quantified in the pellet and the 191 
total amount of zein used for the preparation of nanoparticles. 192 
 193 
Folic acid analysis 194 
The amount of folic acid loaded into the nanoparticles was quantified by HPLC-195 
UV using a previously described analytical method [26] with minor 196 
modifications. Analyses were carried out in an Agilent model 1100 Series LC 197 
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System coupled to a diode-array detector set at 290 nm. The data were 198 
analyzed using ChemStation G2171 v. B.01.03 software (Agilent, USA). The 199 
chromatographic system was equipped with a reverse C18 Alltima column (150 200 
mm x 2.1 mm, particle size 5 μm; Altech, USA) and a Gemini C18 precolumn 201 
(particle size 5 μm; Phenomenex, CA, USA). The mobile phase, pumped at 202 
0.25 mL/min, was a mixture of phosphoric acid (33 mM, pH 2.3) and acetonitrile 203 
under gradient conditions [26]. The column was heated to 40ºC and the 204 
injection volume was 10 μL. Under these conditions, folic acid eluted at 21.2 ± 205 
0.5 min. Calibration curves were designed over the range of 2 and 200 μg/mL 206 
(R2 0.999). The limit of quantification was calculated to be 4.3 µg/mL. 207 
For analysis, 10 mg nanoparticles was dispersed in 1 mL water and centrifuged. 208 
The amount of encapsulated folic acid was calculated by dissolution of the 209 
pellets in 75% ethanol (1 mL). In parallel, the total amount of folic acid in the dry 210 
formulations was quantified by direct digestion of 10 mg formulation with 1 mL 211 
ethanol 75%. In all cases the samples were filtered through 0.45 µm 212 
membranes before analysis. Each sample was assayed in triplicate and the 213 
results are expressed as the amount of resveratrol (µg) per mg of nanoparticles. 214 
The encapsulation efficiency (EE), expressed in percentage, was calculated as 215 
the ratio between the amount of folic acid quantified in the pellets and the total 216 
amount of folic acid quantified in the dry powder.  217 
 218 
In vitro release study 219 
Release experiments were conducted under sink conditions at 37°C using 220 
simulated gastric fluid (SGF; pH 1.2; pepsin 0.32% w/v) and intestinal fluid (SIF; 221 
pH 6.8; pancreatin 1% w/v). The studies were performed under agitation in a 222 
Vortemp 56TM Shaking Incubator (Labnet International Inc., NJ, USA) after the 223 
dispersion of the nanoparticles in the appropriate medium.  224 
For each specific time interval, 20 µg folic acid formulated in nanoparticles were 225 
resuspended in 1 mL of the corresponding simulated fluid. The different 226 
formulations were kept in the SGF for 2 hours before being transferred to SIF. 227 
At different intervals, samples were collected and centrifuged at 17,000 rpm for 228 
20 minutes. The amount of folic acid released was quantified by HPLC from the 229 
supernatants as described above.  230 
 231 
Zein nanoparticles labelling 232 
Radiolabelling of zein nanoparticles (125I-NP-Z) 233 
Zein nanoparticles were radiolabelled with Iodine-125 (125INa) by standard mild 234 
oxidative iodination. For this purpose, 10 mg empty zein nanoparticles were 235 
tagged with 2 iodobeads and 3.5 µL of 125INa in 600 µL of a mixture between 236 
PBS and water for injection (1:2 by vol). After 15 min of incubation, iodine zein 237 
nanoparticles (125I-NP-Z) were obtained.  238 
The stability of the radiolabelling was evaluated by TLC. For this purpose, 125I-239 
NP-Z in dialysis cassettes were introduced in aqueous media and the presence 240 
of free iodide was revealed by TLC. 241 
 242 
Lumogen red loaded in zein nanoparticles (LR-NP-Z) 243 
Zein nanoparticles were fluorescently labelled with Lumogen® F Red 305 (LR-244 
NP-Z). Briefly, 2 mg Lumogen® red in acetone (5 mL) were added to the 245 
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hydroalcoholic solution of zein and lysine. Then, zein nanoparticles were formed 246 
by the addition of 70 mL purified water. The resulting nanoparticles were 247 
purified and dried under the same conditions described above. 248 
The amount of Lumogen® F Red 305 was determined by colorimetry at 249 
wavelength 540 nm in a spectrophotometer Agilent 8453 system (USA). For this 250 
purpose, 10 mg of the formulations were re-suspended in purified water and 251 
centrifuged at 17,000 rpm for 20 min. Pellets were then dissolved in ethanol 252 
75%. For quantification, standard curves of Lumogen red in ethanol 75% were 253 
used (concentration range of 5-30 µg/mL R2 ≥ 0.999).  254 
Prior the use of fluorescently labelled nanoparticles for in vivo studies, the 255 
stability of the marker in the nanoparticles was assessed by incubation in 256 
simulated gastric (pH 1.2) and intestinal (pH 6.8) fluids. 257 
 258 
In vivo distribution study 259 
All of these studies were performed in male Wistar rats obtained from Harlan 260 
(Barcelona, Spain) and the protocols were approved by the Ethical Committee 261 
for Animal Experimentation of the University of Navarra (protocol number 117-262 
12 and 059-13). Prior to the experiment, animals were placed in metabolic 263 
cages and drink provided ad libitum. 264 
For radiolabelled nanoparticles, animals (200-250 g) received a 1 mL single 265 
dose of an aqueous suspension of nanoparticles (10 mg of 125I-NP-Z). As 266 
control, an aqueous suspension of 125I was administered by oral route.  Animals 267 
were anesthetized with isofluorane and place in prone position on the 268 
gammacamera. The gammagraphic studies were performed in a E.cam Dual-269 
Head-Variable-Angle System gammacamera (Siemens Medical Systems, USA) 270 
The images were obtained 2, 24 and 48 hours after the administration of the 271 
radiolabelled nanoparticles.  272 
For fluorescently labelled nanoparticles, a protocol previously described was 273 
used [27]. Thus, the animals received orally a single dose of 30 mg 274 
nanoparticles (LP-NP-Z) dispersed in 1 mL water. Two hours later, the animals 275 
were sacrificed and guts were removed. Jejunum portions of 1 cm were 276 
collected, cleaned with PBS, stored in the tissue proceeding medium O.C.T. 277 
and frozen at -80°C. Each portion was then cut into 5-µm sections on a cryostat 278 
and attached to glass slides. Finally, these samples were fixed with 279 
formaldehyde and incubated with DAPI (4',6-diamidino-2-phenylindole) for 15 280 
minutes before the cover assembly. The presence of both fluorescently loaded 281 
poly(anhydride) nanoparticles in the intestinal mucosa and the cell nuclei dyed 282 
with DAPI were visualized in a fluorescence microscope (Axioimager M1, Zeiss) 283 
with a coupled camera (Axiocam ICc3, Zeiss) and fluorescent source (HBO 284 
100, Zeiss. The images were captured with the software ZEN (Zeiss). 285 
 286 
In vivo pharmacokinetic studies in male Wistar rats 287 
Pharmacokinetic studies 288 
Pharmacokinetic studies were performed in male Wistar rats (200-250 g) 289 
obtained from Harlan (Barcelona, Spain). Studies were approved by the Ethical 290 
Committee for Animal Experimentation of the University of Navarra (protocol 291 
number 014-10) in accordance with the European legislation on animal 292 
experiments. Prior to the experiment, animals were adaptively fed for 1 week 293 
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with free access to a Folic Acid deficient diet (TD 95247, Harlan, USA) and 294 
drinking water (22±2°C; 12-h light and 12-h dark cycles; 50-60% relative 295 
humidity). Previous to the oral administration of the formulations, animals were 296 
fasted overnight to avoid interference with the absorption, allowing free access 297 
to water. 298 
For the pharmacokinetic study, rats were randomly divided into 4 groups of 6 299 
animals each. The experimental groups were an aqueous solution of folic acid 300 
extemporaneously prepared (FA dissolved in PBS) and folic acid-loaded zein 301 
nanoparticles (FA-NP-Z) dispersed in water. As controls, a group of animals 302 
was intravenously administered with a solution of folic acid in PBS and the last 303 
group of rats received PBS (without folic acid) orally. The single folic acid 304 
administered dose was 1 mg/kg body weight either orally with a blunt needle via 305 
the oesophagus into the stomach or intravenously via tail vein. 306 
Blood samples were collected at set times after administration in specific serum 307 
tubes (SARSTEDT Microtube 1,1 mL Z-Gel). Volemia was recovered 308 
intraperitoneally with an equal volume of sterile saline solution pre-heated to 309 
body temperature. Samples were immediately centrifuged at 10,000 rpm for 10 310 
min. Serum was separated into clean tubes and kept frozen at -80 °C until 311 
analysis. 312 
 313 
Determination of folic acid in serum 314 
The amount of folic acid in serum was determined by an Enzyme 315 
Immunoassay. Calibrator and quality control samples were prepared by adding 316 
appropriate volumes of standard folic acid solution in PBS to serum. Calibration 317 
curves were designed over the range 4-450 ng/mL (R2 > 0.996). For analysis, 318 
100 mL of the serum samples were added to each well of the microtiter plate, 319 
followed by the addition of 50 mL folic acid antibody. After incubation for 60 min 320 
at room temperature, the plate was washed three times with the washing 321 
solution (PBS-Tween 20 0.5%). Then, 100 mL conjugate (anti-mouse-IgG-HRP) 322 
was added into each well and after 60 min at room temperature, the plate was 323 
washed again for three times with the washing solution. For the reaction, 100 324 
mL of substrate was added into each well and incubated in the dark for 20 min 325 
at room temperature. The reaction was stopped by the addition of 100 mL 326 
sulphuric acid 0.5 M into each well. Finally, the absorbance was measured at 327 
450 nm in an ELISA reader (Labsystems iEMS Reader MF). 328 
Under these experimental conditions, the limit of quantification of this method 329 
was calculated to be 4 ng/mL. The recovery of folic acid from serum samples 330 
was 90.1 ± 0.3%. Accuracy values during the same day (intraday assay) at low, 331 
medium and high concentrations of FA were always within the acceptable limits 332 
(less than 15%). 333 
 334 
Pharmacokinetic data analysis  335 
The pharmacokinetic analysis of serum concentration plotted against time data 336 
was performed using a non-compartmental model with the WinNonlin 5.2 337 
software (Pharsight Corporation, Mountain View, USA). The following 338 
parameters were estimated: maximal serum concentration (Cmax), time taken to 339 
reach Cmax (Tmax), area under the concentration-time curve from time 0 to ∞ 340 
(AUC), mean residence time (MRT), clearance (Cl), volume of distribution (V) 341 
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and half-life in the terminal phase (t1/2). Furthermore, the relative oral 342 
bioavailability (Fr, expressed in percentage) of folic acid was estimated as the 343 
ratio between the areas under the curve for the oral (AUCoral) and intravenous 344 
(AUCiv) administrations. 345 
 346 
Statistical analysis 347 
The data are expressed as the mean ± standard deviation (SD) of at least three 348 
experiments. The non-parametric Kruskall-Wallis followed by Mann-Whitney U-349 
test with Bonferroni correction was used to investigate statistical differences. In 350 
all cases, p< 0.05 was considered to be statistically significant. All data 351 
processing was performed using SPSS® statistical software (SPSS® 15, 352 
Microsoft, USA).  353 
 354 
 355 
Results 356 
Folic acid loaded zein nanoparticles 357 
Table 1 summarizes the main physicochemical properties of folic acid-loaded 358 
nanoparticles. When folic acid was encapsulated into zein nanoparticles, a 359 
moderate increase in the mean size of the resulting carriers was observed 360 
(about 164 nm for empty nanoparticles vs 193 nm for FA-NP-Z); whereas the 361 
negative zeta potential decreased from -46 mV (control nanoparticles) to -30 362 
mV (folic acid-loaded nanoparticles). The folic acid loading into the zein 363 
nanoparticles (FA-NP-Z) was calculated to be around 54 µg/mg nanoparticle, 364 
with encapsulation efficiency close to 57%. 365 
The morphological analysis by scanning electron microscopy (Figure 1) showed 366 
that folic acid-loaded zein nanoparticles consisted of homogeneous populations 367 
of spherical nanoparticles with a smooth surface and an apparent similar size to 368 
that obtained by photon correlation spectroscopy.  369 
 370 
Table 1 371 
 372 
Figure 1 373 
 374 
In vitro release study 375 
Figure 2 represents the release profile of folic acid from the zein nanoparticles 376 
formulations as cumulative percentage of the vitamin released as a function of 377 
time.  When nanoparticles were incubated in SGF, no release of folic acid was 378 
observed. On the contrary, when zein nanoparticles were assayed in SIF, the 379 
release of folic followed a profile characterized by two different steps. In the first 380 
one, approximately 70% of the loaded folic acid was rapidly released. Then, 381 
after this burst effect, the remaining vitamin was released in a sustained way up 382 
to the end of the experiment (24 hours). 383 
 384 
Figure 2 385 
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 386 
In vivo distribution study of 125I-NP-Z and Lumogen-NP-Z in the gut 387 
mucosa 388 
Figure 3 shows the biodistribution (SPECT-CT images) of free 125-iodine 389 
(Figure 3A) and zein nanoparticles radiolabelled with 125-iodine (Figure 3B) 390 
orally administered to rats. 391 
For those animals treated orally with the control (free 125-iodine), the 392 
radioactivity was always found in their stomach and thyroid.  On the other hand, 393 
the radioactivity associated to zein nanoparticles was visualized in the stomach 394 
2 hours after administration; although, twenty two hours later the radioactive 395 
signal was also found at the thyroid and the distal areas of the colon. Finally, 48 396 
hours after administration, the remaining activity was observed in the thyroid 397 
and stomach of animals, in which the signal was significantly lower than that 398 
observed at the previous times. The activity in the thyroid demonstrates in vivo 399 
physiologic de-iodination of iodine labelled nanoparticles. 400 
 401 
Figure 3 402 
 403 
Figure 4 shows fluorescence microscopy images of jejunum samples of animals 404 
treated with Lumogen® red formulations. Control formulation (an aqueous 405 
suspension of the fluorescent marker) was observed in the lumen of the small 406 
intestine of animals as large aggregates (Figure 4A) and no fluorescence was 407 
visualized in the vicinity of the intestinal epithelium (Figure 4B). On the contrary, 408 
when the fluorescent marker was encapsulated in zein nanoparticles, 409 
fluorescence appeared to be in the protective mucus layer, covering the surface 410 
of the intestinal epithelium (Figures 4C and 4D).  411 
 412 
Figure 4 413 
 414 
Pharmacokinetic studies in Wistar rats 415 
When folic acid was administered orally as aqueous solution, the levels of the 416 
vitamin in the sera of animals increased rapidly during the first 1 h post-417 
administration, in which the Cmax was reached (Figure 5). Then, the vitamin 418 
levels decreased slowly until the end of the experiment (24 h post-419 
administration). For the formulation based on zein nanoparticles, the levels of 420 
folic acid in the sera of animals displayed a similar profile to that observed for 421 
the free folic acid (FA solution). However, the serum levels of the vitamin from 422 
nanoparticles were significantly higher than those observed for the aqueous 423 
solution of folic acid.  424 
 425 
Figure 5 426 
 427 
Table 2 summarizes the pharmacokinetic parameters derived from the analysis 428 
of the data obtained after the administration of the different folic acid 429 
formulations to rats.When folic acid was administrated orally as aqueous 430 
solution, the AUC was 1.4 µg h/mL; whereas, this parameter was 3.0 µg h/mL 431 
when the vitamin was given after its encapsulation in zein nanoparticles.  432 
Similarly, the peak plasma concentration (Cmax) of folic acid in the nanoparticles 433 
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was around 2- times higher than for the vitamin aqueous solution. On the 434 
contrary, other important pharmacokinetic parameters of folic acid (e.g., volume 435 
of distribution, clearance or half-life of the terminal phase) were similar when the 436 
vitamin was administered as aqueous solution or loaded in zein nanoparticles. 437 
Finally, the relative oral bioavailability of folic acid when incorporated in zein 438 
nanoparticles was of about 70%, whereas for the folic acid aqueous solution the 439 
oral bioavailability was only of 35%. 440 
 441 
Table 2 442 
 443 
Discussion 444 
Folic acid, as other weak acid compounds, possesses a pH-dependent aqueous 445 
solubility, being insoluble in aqueous media below pH 5 [28]. In vivo, the pH of 446 
the stomach contents may induce the precipitation of the vitamin in macroscopic 447 
aggregates that, once in the small intestine (pH around 5-6), would be (at least 448 
in part) re-dissolved. However, in these pH conditions, and because of the 449 
hydrophilic nature of the charged molecule, specific transporters are required 450 
for folic acid absorption. These highly specific transporters (the reduced folate 451 
carrier, RFC, and the proton-coupled folate transporter, PCFT) are expressed at 452 
the apical brush-border membrane of the proximal jejunum [29] in which the 453 
absorption of the vitamin takes place [30]. 454 
On the other hand, zein is a biodegradable and biocompatible material, 455 
economic to use and with a “GRAS” status [31]. In addition, zein is an 456 
amphiphilic protein with an important ability to interact with solutes like drugs 457 
[32] or amino acids [33]. Moreover, zein displays mucoadhesive properties [12] 458 
and a relatively high resistance to the effect of digestive enzymes [3].  459 
In this work, zein nanoparticles were prepared under mild conditions by a 460 
desolvation technique after the addition of water to a hydroalcoholic solution of 461 
the protein and lysine. Then nanoparticles were purified and, finally, dried in a 462 
spray-drier apparatus. The presence of lysine was necessary to facilitate the 463 
redispersion of the dry powder in water by simple manual agitation. Under these 464 
experimental conditions, folic acid-loaded zein nanoparticles displayed a mean 465 
size after reconstitution of about 200 nm with a negative zeta potential of -24 466 
mV and a low polydispersity index (Table 1). The folic acid content was close to 467 
54 µg/mg nanoparticles, which is approximately 3-times higher than the payload 468 
reported by Perez-Masiá and collaborators who used nano- and microcapsules 469 
from either whey protein or starch [34]. 470 
Interestingly, the release of folic acid from zein nanoparticles was found to be 471 
dependent of the pH conditions. Thus, under simulated gastric conditions, folic 472 
acid was not released from zein nanoparticles. Nevertheless, when 473 
nanoparticles were incubated in SIF, a burst effect of approximately 70% of the 474 
folic acid content was observed (Figure 2). These findings would be directly 475 
related with the fact that the solubility of folic acid in water is dependent on its 476 
ionization (pKa values of 4.65, 6.75 and 9 [35, 36]). In SIF, the two carboxylic 477 
acid groups of folic acid would be deprotonated, resulting in a negative net 478 
charge similar to that observed for zein nanoparticles. Thus the repulsion 479 
between ionized folic acid and zein would result in a rapid release of the vitamin 480 
from the nanoparticles. On the other hand, after this burst effect of folic acid in 481 
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SIF, the remaining vitamin (around 30%) was slowly released till the end of the 482 
experiment (Figure 2). This fact might be related with the capability of folic acid 483 
to bind to proteins, such as albumins [37] and caseins [38], through hydrogen 484 
and hydrophobic bonds. To the best of our knowledge, there is no information 485 
suggesting the presence of binding sites for folic acid in zein; however, in 486 
accordance with the release data, we can hypothesize that a fraction of the 487 
loaded folic acid would be stabilized within the protein matrix by non-covalent 488 
binding interactions. Therefore, the remaining fraction would be released slowly 489 
during the degradation of the nanoparticles. 490 
In the present study, the relative oral bioavailability of folic acid formulated as 491 
aqueous solution was calculated to be 35%. The highest serum concentration of 492 
folic acid occurred 1 hour after the administration, and values returned to 493 
baseline after 24 hours. These results are in line with previous data reported in 494 
the literature by other research groups [39, 40]. On the other hand, zein 495 
nanoparticles provided higher folic acid levels than the aqueous solution. As a 496 
consequence, the relative oral bioavailability of folic acid when administered 497 
after its encapsulation in zein nanoparticles was calculated to be close to 70% 498 
and 2-times higher than when administered as oral solution (Table 2). Other 499 
important aspects to highlight are that both the serum curve profiles (Figure 5) 500 
and the primary pharmacokinetic parameters (volume of distribution, clearance, 501 
serum half-life) of folic acid were independent on the formulation tested 502 
(aqueous solution and zein nanoparticles). Thus, the differences in the oral 503 
bioavailability of the vitamin might only be due to the capabilities of zein 504 
nanoparticles to both give protection against the macroscopic aggregation by 505 
precipitation of the vitamin in acidic conditions and act as carriers to transport 506 
the folic acid to the absorptive membrane.   507 
When orally administered, zein nanoparticles remained within the 508 
gastrointestinal tract for a period of at least 24 h post-administration (Figure 3). 509 
The absence of signals in the liver, spleen and lungs of animals suggested that 510 
zein nanoparticles were not capable of entering into the circulation from the gut 511 
(Figure 3). Within the gastrointestinal tract of animals, and in accordance with 512 
data from fluorescently labelled nanoparticles, these carriers would be capable 513 
of interacting with the mucus layer protecting the epithelium surface (Figures 4C 514 
and 4D). This last observation would be in line with previous data suggesting 515 
the mucoadhesive properties of zein [12, 41, 42]. 516 
To sum up, zein nanoparticles would be capable of transporting the cargo to the 517 
small intestine. Once there, the mucoadhesive properties of zein would be 518 
responsible for an increase in the residence time of these carriers in the upper 519 
region of the gastrointestinal tract, in which the absorption of folic acid is 520 
favored [29, 30]. 521 
 522 
 523 
Conclusions 524 
Zein nanoparticles offer adequate properties for oral delivery purposes. Orally 525 
administered, these nanoparticles are localized within the gut in close contact 526 
with the gut mucosa. Regarding folic acid, its encapsulation in zein 527 
nanoparticles improved its relative oral bioavailability about 2-fold when 528 
compared with an aqueous solution of the vitamin. This fact would be related 529 
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with the capability of these nanoparticles to reach the small intestine mucosa 530 
and develop mucoadhesive interactions. 531 
 532 
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Figure Captions 665 
 666 
Figure 1. Scanning electron microscopy (SEM) microphotographs obtained from 667 
folic acid-loaded zein nanoparticles. 668 
 669 
Figure 2. Folic acid release profile from zein nanoparticles after incubation in 670 
simulated gastric fluid (0-2 h) and intestinal fluid (2-48 h) under sink conditions. 671 
Data are expressed as the mean ±SD, n=3. 672 
 673 
Figure 3. Biodistribution of 125-Iodine control and radiolabelled zein 674 
nanoparticles. Panels A and B show gammacamera images after oral 675 
administration of 125-Iodine (3A) and 10 mg 125I-NP-Z (3B) at 2, 24 and 48 676 
hours post administration.  677 
 678 
Figure 4. Fluorescence microscopy images of jejunum samples 2 hours after 679 
the oral administration of either a Lumogen® red aqueous suspension (A and B) 680 
or zein nanoparticles fluorescently labelled with Lumogen® red. Nuclei of cells 681 
were stained blue with DAPI. 682 
 683 
Figure 5. Folic acid serum concentration vs time after a single oral 684 
administration of 1 mg/kg for the different formulations tested.  i) Folic acid 685 
solution in PBS (●; FA sol), ii) Folic acid loaded in zein nanoparticles (▲; FA-686 
NP-Z). Data expressed as the mean ± SD; (n= 6). 687 
 688 
 689 
 690 
 691 
   692 
 17 
 
Tables 693 
Table 1. Physicochemical characterization of zein nanoparticles. NP-Z: empty 694 
nanoparticles; FA: folic acid; FA-NP-Z: folic acid-loaded zein nanoparticles. 695 
Data expressed as mean ± SD, n=3. 696 
 697 
 Size 
a 
(nm) 
PDI  
(nm) 
Zeta 
Potential b 
(mV) 
FA loading c 
(µg FA/ mg 
NP) 
EE d 
(%) 
NP-Z 164 ± 2 0.07 ± 0.01 -46.0 ± 1.5 - - 
FA-NP-Z 193 ± 3 0.20 ± 0.06 -29.3 ± 3.1 54 ± 7 57 ± 6 
a Determination of the nanoparticle size (nm) by photon correlation spectroscopy 698 
b Determination of the zeta potential (mV) by electrophoretic laser Doppler anemometry 699 
c Amount of folic acid loaded in the nanoparticles (µg FA/mg nanoparticles) 700 
d Encapsulation efficiency (%) 701 
 702 
  703 
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Table 2. Pharmacokinetic parameters of folic acid administered as single dose of 1 mg/kg by the intravenous or oral routes as 704 
aqueous solution or loaded in zein nanoparticles. Data are expressed as mean ± S.D, (n=6). 705 
 706 
 Route Cmax (μg/mL) 
Tmax 
(h) 
AUC 
(μg h/mL) 
T½ 
(h) 
Cl 
(L/h) 
Vd 
(L) 
MRT 
(h) 
Fr 
(%) 
PBS oral - - - - - - - - 
FA iv iv 5.5 ± 2.7 ** 0.0 3.7 ± 0.4 ** 1.2±0.6 0.06±0.01 0.10±0.05 0.9±0.2 ** 100 
FA sol oral 0.2 ± 0.0 1.0 ± 0.6 1.3 ± 0.3 5.9±1.9 0.06±0.02 0.44±0.07 5.7±1.6 35 
FA-NP-Z oral 0.4 ± 0.1 * 1.0 ± 0.0 3.0 ± 1.0 * 7.1±2.6 0.05±0.01 0.49±0.11 6.5±1.3 70 
Cmax: peak plasma concentration; Tmax: time to reach plasma concentration; AUC: area under the curve; t½: half-life of the terminal phase; Cl: 707 
clearance; Vd: volume of distribution; MRT: mean residence time Fr: relative oral bioavailability 708 
* Significant differences (p<0.05) vs FA sol (Mann-Whitney-U) 709 
**Significant differences (p<0.01) vs FA sol (Mann-Whitney-U) 710 
 711 
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